340 related articles for article (PubMed ID: 23271036)
21. Clinical significance of elevated serum chromogranin A levels.
Syversen U; Ramstad H; Gamme K; Qvigstad G; Falkmer S; Waldum HL
Scand J Gastroenterol; 2004 Oct; 39(10):969-73. PubMed ID: 15513336
[TBL] [Abstract][Full Text] [Related]
22. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
23. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
Kimura N; Hoshi S; Takahashi M; Takeha S; Shizawa S; Nagura H
J Urol; 1997 Feb; 157(2):565-8. PubMed ID: 8996358
[TBL] [Abstract][Full Text] [Related]
24. Limitations of Chromogranin A in clinical practice.
Marotta V; Nuzzo V; Ferrara T; Zuccoli A; Masone M; Nocerino L; Del Prete M; Marciello F; Ramundo V; Lombardi G; Vitale M; Colao A; Faggiano A
Biomarkers; 2012 Mar; 17(2):186-91. PubMed ID: 22303881
[TBL] [Abstract][Full Text] [Related]
25. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
26. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
27. Measurements of chromogranin B can serve as a complement to chromogranin A.
Stridsberg M; Eriksson B; Fellström B; Kristiansson G; Tiensuu Janson E
Regul Pept; 2007 Mar; 139(1-3):80-3. PubMed ID: 17116339
[TBL] [Abstract][Full Text] [Related]
28. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A.
Popovici T; Moreira B; Schlageter MH; Bories PN
Clin Biochem; 2014 Jan; 47(1-2):87-91. PubMed ID: 24201067
[TBL] [Abstract][Full Text] [Related]
29. Chromogranin A in gastrinomas: Promises and pitfalls.
Rehfeld JF
Clin Chim Acta; 2015 Jun; 446():15-20. PubMed ID: 25861845
[TBL] [Abstract][Full Text] [Related]
30. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.
Arnold R; Wilke A; Rinke A; Mayer C; Kann PH; Klose KJ; Scherag A; Hahmann M; Müller HH; Barth P
Clin Gastroenterol Hepatol; 2008 Jul; 6(7):820-7. PubMed ID: 18547872
[TBL] [Abstract][Full Text] [Related]
31. Chromogranin A assay in clinical practice.
d'Herbomez M; Do Cao C; Vezzosi D; Borzon-Chasot F; Baudin E;
Ann Endocrinol (Paris); 2010 Sep; 71(4):274-80. PubMed ID: 20538257
[TBL] [Abstract][Full Text] [Related]
32. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
[TBL] [Abstract][Full Text] [Related]
34. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours.
Nikou GC; Marinou K; Thomakos P; Papageorgiou D; Sanzanidis V; Nikolaou P; Kosmidis C; Moulakakis A; Mallas E
Pancreatology; 2008; 8(4-5):510-9. PubMed ID: 18765956
[TBL] [Abstract][Full Text] [Related]
35. Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors.
Conlon JM
Regul Pept; 2010 Nov; 165(1):5-11. PubMed ID: 19931574
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression.
Ramachandran R; Bech P; Murphy KG; Caplin ME; Patel M; Vohra S; Khan MS; Dhillo WS; Sharma R; Palazzo FF; Win Z; Tan T; Khoo B; Meeran K; Frilling A; Ghatei MA; Bloom SR; Martin NM
J Clin Endocrinol Metab; 2015 Apr; 100(4):1520-8. PubMed ID: 25664601
[TBL] [Abstract][Full Text] [Related]
37. Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Tian T; Gao J; Li N; Li Y; Lu M; Li Z; Lu Z; Li J; Shen L
PLoS One; 2016; 11(5):e0154679. PubMed ID: 27159453
[TBL] [Abstract][Full Text] [Related]
38. Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana D; Nori F; Piscitelli L; Morselli-Labate AM; Pezzilli R; Corinaldesi R; Tomassetti P
J Clin Oncol; 2007 May; 25(15):1967-73. PubMed ID: 17513802
[TBL] [Abstract][Full Text] [Related]
39. Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients.
Chou WC; Hung YS; Hsu JT; Chen JS; Lu CH; Hwang TL; Rau KM; Yeh KY; Chen TC; Sun CF
Neuroendocrinology; 2012; 95(4):344-50. PubMed ID: 22343505
[TBL] [Abstract][Full Text] [Related]
40. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.
Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L
Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
